Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2026-05-22 Earnings Release
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
Press Release and Presentation On Financials
Earnings Release Classification · 91% confidence The document is a press release announcing the company’s Q4 and full‐year FY26 financial results, summarizing key metrics (revenue, EBITDA, PAT, segment performance) and providing commentary. It does not contain full financial statements or detailed management discussion as in an interim or annual report, nor is it a transcript or regulatory filing. This aligns with the definition of an Earnings Release (Code: ER). FY 2026
2026-05-22 English
Press Release
Earnings Release Classification · 94% confidence The document is a May 22, 2026 press release filed under SEBI LODR Regulation 30 announcing Q4 and full year FY26 financial and operational results of Jubilant Pharmova. It contains key highlights and summary financial metrics for the quarter and year, along with commentary by the chairmen. It is not the full annual or interim report, nor a certification or notice of publication, but the initial earnings announcement. Therefore it fits the Earnings Release category. FY 2026
2026-05-22 English
Appointment
Board/Management Information Classification · 92% confidence The document is a compliance filing under SEBI Listing Regulations (Regulation 30) announcing the outcome of a Board meeting. It details the resignation of the current CFO and appointment of a new CFO as Key Managerial Personnel. There are no financial statements or earnings figures, but rather a change in senior management. This matches the Board/Management Information category.
2026-05-22 English
Change in CFO
Board/Management Information Classification · 92% confidence The document is a SEBI Regulation 30 disclosure announcing the resignation of the incumbent CFO and appointment of a new CFO (Key Managerial Personnel). This falls squarely under announcements of senior management changes rather than a full report or earnings release. Therefore, it is classified as Board/Management Information (MANG).
2026-05-22 English
Appointment of MD and JMD
Board/Management Information Classification · 85% confidence The document is an official disclosure under SEBI Listing Regulations providing the outcome of a board meeting, specifically announcing the re-appointment of the Managing Director and Joint Managing Director. It details changes in senior management appointments, profiles, and terms of appointment. This fits the definition of a Board/Management Information filing.
2026-05-22 English
Outcome of Board Meeting
Board/Management Information Classification · 91% confidence The document is a Regulation 30 disclosure under SEBI Listing Regulations summarizing the outcome of a Board meeting, specifically the re-appointment of two executives as Managing Director and Joint Managing Director. This is an announcement of changes in senior management (board/management information) rather than a financial report, call transcript, or other category.
2026-05-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.